MYGN Q1 2026 Earnings Call Summary

Myriad Genetics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: Reported revenue of $200.4 million, within guidance and representing a 2% year-over-year growth.
Testing Volume: Delivered 385,000 test results, with hereditary cancer testing volumes growing 10% (affected) and 16% (unaffected).
Gross Margin: Maintained a solid gross margin of 68.7%, consistent with full-year guidance.
Adjusted EBITDA: Reported an adjusted EBITDA loss of $4.5 million and an adjusted EPS loss of $0.09.
Cash Position: Strong liquidity with $199 million available for strategic investments.

2. Strategic Updates and Business Highlights

Cancer Care Continuum Focus: Myriad has prioritized cancer screening and diagnosis, investing in commercial capabilities and R&D for product development.
Leadership Enhancements: Strengthened the organization with experienced leaders in oncology and genomics, including the appointment of Brian Donnelly as Chief Commercial Officer.
Product Launches:
- Launched Precise MRD for breast cancer, with plans to expand to colorectal and renal cancers in Q3.
- Upcoming launch of AI-enhanced Prolaris prostate cancer test.
- Early access testing for FirstGene, a comprehensive prenatal screening test, with a full launch expected in the second half of 2026.
Mental Health Growth: GeneSight test revenue grew 24% year-over-year, driven by improved reimbursement trends and increased clinician engagement.

3. Forward Guidance and Outlook

2026 Financial Guidance: Reaffirmed revenue guidance of $860 million to $880 million and adjusted EBITDA of $37 million to $49 million.
Second Half Expectations: Anticipates sequential revenue growth in low single digits for Q2, with acceleration expected in the latter half of the year due to expanded commercial efforts and product launches.

4. Challenges and Points of Concern

Prenatal Testing Decline: Prenatal testing revenue decreased 15% year-over-year, attributed to operational disruptions and a new ordering system. However, there are signs of stabilization.
Weather Impact: Adverse weather conditions in Q1 had a marginal impact on testing volumes, particularly in the Northeast and Midwest.
Operational Efficiency: Adjusted operating expenses increased by $8 million year-over-year due to strategic investments, raising concerns about balancing growth with profitability.

5. Notable Q&A Insights

Revenue Growth Drivers: Management highlighted strong growth in hereditary cancer testing and GeneSight, with expectations for improved performance in the prenatal segment driven by FirstGene and a dedicated sales force.
Sales Team Expansion: Over 100 new account executives were added, primarily focused on the Cancer Care Continuum, with expectations for gradual productivity improvements.
Market Positioning: The upcoming AI-enabled Prolaris test is expected to enhance the product offering and competitive positioning in prostate cancer care.
Reimbursement Strategies: Continued efforts to improve reimbursement dynamics for GeneSight and upcoming products, with a focus on leveraging biomarker legislation for better coverage.

Overall, Myriad Genetics is focused on strengthening its position in the cancer care market while navigating challenges in the prenatal segment and managing operational expenses amidst significant strategic investments.

MYGN — Myriad Genetics, Inc.